Real World Evidence Study of SYN023 in Children Exposed to Rabies
Recruiting
Observational Study
Rabies Post-exposure Prophylaxis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 0 – 17
- Sex
- Any
- Study type
- Observational
- Participants needed
- 232 (estimated)
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study is an open-label, prospective, multi-center design. The goal is to evaluate the long-term clinical survival outcomes at 3 months and 1 year in individuals under 18 years of age with WHO Category III rabies exposure who have received real-world Post-Exposure Prophylaxis (PEP) with Zamerovimab and Mazorelvimab Injection / other passive immunization products combined with the…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity;
2. Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is \<7 days;
3. Have completed…
Contacts